



**ALEMBIC PHARMACEUTICALS LIMITED**  
 Regd. Office: Alembic Road, Vadodara 390 003  
 CIN: L24230GJ2010PLC061123  
 Ph #: 0265 2280550 Fax #: 0265 2282506  
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

Rs. in Lacs

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2015

Rs. in lacs

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>						
	Domestic	32,206	32,549	29,281	95,090	89,864	117,394
	Exports	58,456	60,603	21,233	146,908	63,320	85,681
	Total	90,662	93,152	50,514	241,998	153,184	203,075
	Less : Excise Duty	965	990	395	2,746	893	1,505
	Net Sales / Income from Operations	89,697	92,162	50,119	239,252	152,291	201,570
	<b>(b) Other Operating Income</b>	72	92	83	257	229	330
	<b>Total Income from Operations</b>	<b>89,769</b>	<b>92,254</b>	<b>50,202</b>	<b>239,509</b>	<b>152,520</b>	<b>201,900</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of Materials consumed	19,059	18,679	12,361	52,973	42,590	54,049
	(b) Purchase of stock-in-trade	5,156	7,832	6,395	19,573	19,168	24,663
	(c) Changes in Inventories in trade and work in progress	(3,106)	(3,891)	(1,399)	(7,496)	(7,736)	(7,289)
	(d) Employee benefits expense	11,190	11,474	7,658	31,151	22,412	29,657
	(e) Research and Development Expense	4,554	5,734	2,559	14,311	8,083	10,903
	(f) Depreciation & Amortization Expense	2,161	1,325	1,190	4,775	3,345	4,441
	(g) Other Expenses	13,490	18,433	12,161	44,749	36,863	49,136
	<b>Total Expenses</b>	<b>52,504</b>	<b>59,585</b>	<b>40,924</b>	<b>160,036</b>	<b>124,725</b>	<b>165,560</b>
<b>3</b>	<b>Profit from Operations before Other Income, finance costs &amp; exceptional items</b>	<b>37,265</b>	<b>32,669</b>	<b>9,278</b>	<b>79,473</b>	<b>27,795</b>	<b>36,340</b>
<b>4</b>	Other Income	280	5	13	289	45	57
<b>5</b>	<b>Profit from ordinary activities before finance costs &amp; exceptional items</b>	<b>37,545</b>	<b>32,674</b>	<b>9,290</b>	<b>79,762</b>	<b>27,840</b>	<b>36,397</b>
<b>6</b>	Finance Costs	67	53	(42)	156	106	111
<b>7</b>	<b>Profit from ordinary activities before tax</b>	<b>37,478</b>	<b>32,621</b>	<b>9,332</b>	<b>79,606</b>	<b>27,734</b>	<b>36,286</b>
<b>8</b>	<b>Tax Expense</b>						
	Provision for Current Tax	7,844	7,354	1,933	17,074	5,782	7,625
	MAT Credit Reversal / (Entitlement)	1,060	(488)	-	-	-	(739)
	Provision for Deferred Tax Liability	561	488	-	1,621	-	739
<b>9</b>	<b>Net Profit from ordinary activities after tax</b>	<b>28,013</b>	<b>25,267</b>	<b>7,399</b>	<b>60,911</b>	<b>21,952</b>	<b>28,661</b>
<b>10</b>	Paid up Equity Share Capital ( Face value of share Rs. 2/- )	3,770	3,770	3,770	3,770	3,770	3,770
<b>11</b>	Reserves excluding Revaluation Reserve						79,586
<b>12</b>	Basic & Diluted EPS (Not Annualised)	14.86	13.40	3.92	32.31	11.64	15.20

**Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2015**

Rs. in Lacs

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>						
	Domestic	32,206	32,549	29,281	95,090	89,864	117,394
	Exports	60,860	69,225	22,209	158,781	66,114	89,379
	Total	93,066	101,774	51,490	253,871	155,978	206,773
	Less : Excise Duty	965	990	395	2,746	893	1,505
	Net Sales / Income from Operations	92,101	100,784	51,095	251,125	155,085	205,268
	<b>(b) Other Operating Income</b>	72	92	83	257	229	344
	<b>Total Income from Operations</b>	<b>92,173</b>	<b>100,876</b>	<b>51,178</b>	<b>251,382</b>	<b>155,314</b>	<b>205,612</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of Materials consumed	19,059	18,679	12,361	52,973	42,590	54,049
	(b) Purchase of stock-in-trade	4,649	7,840	6,471	19,074	19,243	24,692
	(c) Changes in Inventories in trade and work in progress	(3,106)	(3,891)	(1,399)	(7,496)	(7,736)	(7,289)
	(d) Employee benefits expense	11,698	11,961	7,916	32,444	23,154	30,676
	(e) Research and Development Expense	7,012	7,796	3,051	19,602	9,113	12,162
	(f) Depreciation & Amortization Expense	2,165	1,327	1,190	4,781	3,345	4,441
	(g) Other Expenses	14,401	20,888	12,621	48,517	38,448	51,025
	<b>Total Expenses</b>	<b>55,877</b>	<b>64,600</b>	<b>42,211</b>	<b>169,895</b>	<b>128,157</b>	<b>169,757</b>
<b>3</b>	<b>Profit from Operations before Other Income, finance costs &amp; exceptional items</b>	<b>36,295</b>	<b>36,276</b>	<b>8,967</b>	<b>81,487</b>	<b>27,157</b>	<b>35,856</b>
<b>4</b>	Other Income	280	5	13	289	45	230
<b>5</b>	<b>Profit from ordinary activities before finance costs &amp; exceptional items</b>	<b>36,575</b>	<b>36,281</b>	<b>8,980</b>	<b>81,776</b>	<b>27,202</b>	<b>36,086</b>
<b>6</b>	Finance Costs	104	73	(18)	238	142	178
<b>7</b>	<b>Profit from ordinary activities before tax</b>	<b>36,471</b>	<b>36,208</b>	<b>8,998</b>	<b>81,538</b>	<b>27,060</b>	<b>35,908</b>
<b>8</b>	<b>Tax Expense</b>						
	Provision for Current Tax	7,891	7,354	1,933	17,121	5,804	7,635
	MAT Credit Reversal / (Entitlement)	1,060	(488)	-	-	-	(739)
	Provision for Deferred Tax Liability	561	488	-	1,621	-	739
<b>9</b>	<b>Net Profit from ordinary activities after tax</b>	<b>26,960</b>	<b>28,854</b>	<b>7,065</b>	<b>62,796</b>	<b>21,256</b>	<b>28,273</b>
<b>10</b>	Share of Profit / (loss) of associates	(11)	35	1	30	4	20
<b>11</b>	<b>Net Profit after tax and share of profit / (loss) of associates</b>	<b>26,949</b>	<b>28,890</b>	<b>7,066</b>	<b>62,826</b>	<b>21,260</b>	<b>28,293</b>
<b>12</b>	Paid up Equity Share Capital ( Face value of share Rs 2/- )	3,770	3,770	3,770	3,770	3,770	3,770
<b>13</b>	Reserves excluding Revaluation Reserve						84,694
<b>14</b>	Basic & Diluted EPS (Not Annualised)	14.30	15.32	3.75	33.33	11.28	15.01

**Notes :**

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.
- 2 The Company has opted to furnish consolidated financial results, pursuant to option made available as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Standalone Financial Results are available on the company's website [www.alembic-india.com](http://www.alembic-india.com).

The key information on the standalone financial results are as under:

Rs in Lacs

Particulars	Quarter Ended			Period Ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net Sales / Income from Operations	89,769	92,254	50,202	239,509	152,520	201,900
Profit Before Tax	37,478	32,621	9,332	79,606	27,734	36,286
Profit After Tax	28,013	25,267	7,399	60,911	21,952	28,661

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

**For Alembic Pharmaceuticals Limited**

Place : Vadodara

Date : 21st January, 2016

**Chirayu Amin**

**Chairman and Managing Director**

Visit us at [www.alembic-india.com](http://www.alembic-india.com)